<DOC>
	<DOCNO>NCT01243008</DOCNO>
	<brief_summary>IXODES GmbH intend develop SHB001 , azithromycin dermal formulation order prevent Lyme disease early stage infection tick bite .</brief_summary>
	<brief_title>Safety , Skin Plasma Concentration Azithromycin Dermal Formulation</brief_title>
	<detailed_description>In study two consecutive cohort treat : - Cohort 1 : 8 volunteer - Cohort 2 : 24 volunteer , divide 3 group 8 subject The study conduct follow three phase : 1 . Treatment cohort 1 : The aim establish maximal tolerate dose ( MTD ) local treatment azithromycin dermal formulation . 1 . Treatment cohort 1 azithromycin dermal formulation follow 2 . Assessment local safety within 7 day follow first treatment 3 . The maximal tolerate dose ( MTD ) determine 2 . Treatment cohort 2 : The aim confirm local tolerance select dos evaluate local skin plasma concentration azithromycin application SHB001 dermal formulation . 1 . Treatment cohort 2 azithromycin dermal formulation maximal tolerate dose ( MTD ) , dose one concentration low maximal tolerate dose ( MTD ) placebo 2 . Skin biopsy treat skin area take PK assessment 3 . Study completion examination</detailed_description>
	<mesh_term>Lyme Disease</mesh_term>
	<criteria>Main inclusion criterion : Male female healthy volunteer , age 18 70 year Main exclusion criterion : A known hypersensitivity azithromycin , erythromycin macrolide antibiotic A know hypersensitivity lidocaine Treatment route macrolide antibiotic within last 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Lyme disease</keyword>
	<keyword>Borreliosis</keyword>
	<keyword>Azithromycin</keyword>
</DOC>